Quantification of Calcyclin and Heat Shock Protein 90 in Sera from Women with and without Preeclampsia by Mass Spectrometry

Abstract

Purpose The objective of present study is to determine serum levels and placental distribution of two interacting proteins calcyclin and heat shock protein 90 in preeclampsia. Experimental design Maternal serum levels of calcyclin and heat shock protein 90 are compared throughout pregnancy from the first trimester till term among women with preeclampsia (n = 43) and age‐matched normotensive pregnant controls (n = 46). A serum‐based 2D LC‐MS assay using Parallel Reaction Monitoring is applied to quantify both calcyclin and heat shock protein 90. Results Serum levels of calcyclin are significantly lower in patients with preeclampsia in the second trimester of pregnancy as compared to controls (p < 0.05). Serum levels of heat shock protein 90 are significantly higher in patients with preeclampsia in the third trimester as compared to controls (p < 0.001). Conclusion and clinical relevance Both interacting proteins calcyclin and heat shock protein 90 are notably changed in preeclamptic patients compared to controls. Calcyclin is already decreased before the onset of preeclampsia in the second trimester and HSP90 is strongly increased in the third trimester. This suggests that these proteins may play a role in the pathogenesis of preeclampsia and ought to be investigated in large cohort studies as molecular biomarkers.

Circulating heat shock protein 27 (HSPB1) levels in prediction of pre‐eclampsia: A pilot study

“…There are few and controversial reports about HSPC levels in pre‐eclampsia. Some authors have reported a strong increase of HSPC1 in serum samples from women with pre‐eclampsia in the third‐trimester of pregnancy using mass spectrometry 17 . On the other hand, decreased HSPC mRNA serum levels were found in women with pre‐eclampsia at delivery 16 .…”

“…Hromadnikova et al 16 reported the upregulation of HSPC1 mRNA in placental tissue and the downregulation in peripheral blood of patients with pre‐eclampsia. On the other hand, Güzel et al 17 have shown that maternal serum levels of HSPC1 were significantly higher in patients with pre‐eclampsia in the third trimester of gestation compared with normotensive pregnant control women, suggesting that HSPC1 may play a role in the pathogenesis of the disease 17 …”

“…On the other hand, Güzel et al 17 have shown that maternal serum levels of HSPC1 were significantly higher in patients with pre-eclampsia in the third trimester of gestation compared with normotensive pregnant control women, suggesting that HSPC1 may play a role in the pathogenesis of the disease. 17 Among the candidate serum markers for early detection of preeclampsia, placental protein 13 (PP13) has been one of the most commonly studied. PP13 is produced by syncytiotrophoblasts and it is involved in normal placentation and maternal spiral artery remodeling.…”

S100A6, Calumenin and Cytohesin 2 as Biomarkers for Cutaneous Involvement in Systemic Sclerosis Patients: A Case Control Study

“…Significant expression of S100A6 was observed also in placenta of women diagnosed with preeclampsia, and its expression is increased in oxidative stress response. [ 17 ]. S100A6 was much higher in Ssc patients compared to healthy controls.…”

Cerebrospinal Fluid of Preeclamptic and Normotensive Pregnant Women Compared to Nonpregnant Women Analyzed with Mass Spectrometry

“…For instance, Calcyclin (S100A6) and Galectin 13 (PP13) are both calcium-binding proteins that have been mentioned before to be involved in PE. 28 , 29 Calcium and magnesium are administered to PE women. The literature shows that the administration of calcium might have some beneficial effect, but is not a remedy.…”